These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

64 related articles for article (PubMed ID: 8507135)

  • 21. The pharmacokinetics of intravesical and oral oxybutynin chloride.
    Massad CA; Kogan BA; Trigo-Rocha FE
    J Urol; 1992 Aug; 148(2 Pt 2):595-7. PubMed ID: 1640530
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comparison of the effectiveness and side-effects of tolterodine and oxybutynin in children with detrusor instability.
    Kilic N; Balkan E; Akgoz S; Sen N; Dogruyol H
    Int J Urol; 2006 Feb; 13(2):105-8. PubMed ID: 16563131
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Questionnaire-based survey of lifetime-prevalence and character of allergic drug reactions in German children.
    Lange L; Koningsbruggen SV; Rietschel E
    Pediatr Allergy Immunol; 2008 Nov; 19(7):634-8. PubMed ID: 18221471
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [The use of intravesical oxybutynin hydrochloride in patients with neurogenic bladder managed by intermittent catheterization].
    Yokoyama O; Ishiura Y; Nakamura Y; Ohkawa M
    Hinyokika Kiyo; 1995 Jul; 41(7):521-4. PubMed ID: 7668182
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Antiviral drugs in influenza: an adjunct to vaccination in some situations.
    Prescrire Int; 2006 Feb; 15(81):21-30. PubMed ID: 16548114
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Frequency of wetting is predictive of response to anticholinergic treatment in children with overactive bladder.
    Van Arendonk KJ; Austin JC; Boyt MA; Cooper CS
    Urology; 2006 May; 67(5):1049-53; discussion 1053-4. PubMed ID: 16698366
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Efficacy and safety of oxybutynin chloride topical gel for overactive bladder: a randomized, double-blind, placebo controlled, multicenter study.
    Staskin DR; Dmochowski RR; Sand PK; Macdiarmid SA; Caramelli KE; Thomas H; Hoel G
    J Urol; 2009 Apr; 181(4):1764-72. PubMed ID: 19233423
    [TBL] [Abstract][Full Text] [Related]  

  • 28. An extended-release formulation of oxybutynin chloride for the treatment of overactive urinary bladder.
    Goldenberg MM
    Clin Ther; 1999 Apr; 21(4):634-42. PubMed ID: 10363730
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Sulfasalazine desensitization in children and adolescents with chronic inflammatory bowel disease.
    Tolia V
    Am J Gastroenterol; 1992 Aug; 87(8):1029-32. PubMed ID: 1353658
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Long-term prospective randomized study comparing two different regimens of oxybutynin as a treatment for detrusor overactivity.
    Salvatore S; Khullar V; Cardozo L; Milani R; Athanasiou S; Kelleher C
    Eur J Obstet Gynecol Reprod Biol; 2005 Apr; 119(2):237-41. PubMed ID: 15808387
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Histologic studies of intravesical oxybutynin in the rabbit.
    Landau EH; Fung LC; Thorner PS; Mittelman MW; Jayanthi VR; Churchill BM; McLorie GA; Steckler RE; Khoury AE
    J Urol; 1995 Jun; 153(6):2022-4. PubMed ID: 7752387
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Adverse effects of voriconazole: analysis of the French Pharmacovigilance Database.
    Eiden C; Peyrière H; Cociglio M; Djezzar S; Hansel S; Blayac JP; Hillaire-Buys D;
    Ann Pharmacother; 2007 May; 41(5):755-63. PubMed ID: 17456542
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A refined symptom-based approach to diagnose pulmonary tuberculosis in children.
    Marais BJ; Gie RP; Hesseling AC; Schaaf HS; Lombard C; Enarson DA; Beyers N
    Pediatrics; 2006 Nov; 118(5):e1350-9. PubMed ID: 17079536
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Can oxybutynin cause peripheral neuropathy?
    Patel HR; Albehussi S; Arya M; Miller RA
    J Urol; 2002 Aug; 168(2):646. PubMed ID: 12131334
    [No Abstract]   [Full Text] [Related]  

  • 35. Spectrum of central anticholinergic adverse effects associated with oxybutynin: comparison of pediatric and adult cases.
    Gish P; Mosholder AD; Truffa M; Johann-Liang R
    J Pediatr; 2009 Sep; 155(3):432-4. PubMed ID: 19732583
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Oxybutynin chloride in pediatrics: extenuating circumstances].
    Aubert D
    Arch Fr Pediatr; 1988 May; 45(5):375-6. PubMed ID: 3415420
    [No Abstract]   [Full Text] [Related]  

  • 37. NTP Toxicology and Carcinogenesis Studies of Coumarin (CAS No. 91-64-5) in F344/N Rats and B6C3F1 Mice (Gavage Studies).
    National Toxicology Program
    Natl Toxicol Program Tech Rep Ser; 1993 Sep; 422():1-340. PubMed ID: 12616289
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pharmacokinetics and pharmacodynamics of once-daily controlled-release oxybutynin and immediate-release oxybutynin.
    Reiz JL; Salem P; Darke AC
    J Clin Pharmacol; 2007 Mar; 47(3):351-7. PubMed ID: 17322147
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Propiverine vs oxybutynin for treating neurogenic detrusor overactivity in children and adolescents: results of a multicentre observational cohort study.
    Madersbacher H; Mürtz G; Alloussi S; Domurath B; Henne T; Körner I; Niedeggen A; Nounla J; Pannek J; Schulte-Baukloh H; Schultz-Lampel D; Bock P; Strugala G
    BJU Int; 2009 Mar; 103(6):776-81. PubMed ID: 19007380
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Epistaxis as a side effect of oxybutynin in children: report of two cases.
    Batista JE; Caffaratti J; Garat JM
    Neurourol Urodyn; 1994; 13(1):85-6. PubMed ID: 8156079
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.